Cover Image
市場調查報告書

市場進入的課題:氣喘、COPD (美國)

Market Access Impact (US) [Asthma/COPD]

出版商 FirstWord 商品編碼 531816
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:氣喘、COPD (美國) Market Access Impact (US) [Asthma/COPD]
出版日期: 2017年07月01日 內容資訊: 英文
簡介

本報告提供美國的呼吸系統科醫生、基層護理醫生100名為對象氣喘、COPD治療藥的處方趨勢調查做,與市場進入的各種障礙進行著處方的影響,主要12品牌藥的處方相關比較分析、個別分析

調查對象

  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Advair (fluticasone/salmetrol; GSK)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Tudorza (aclidinium; AstraZeneca)
  • Anoro (umeclidinium/vilanterol; GSK)
  • Arcapta (indacaterol; Novartis)
  • Utibron (indacaterol/glycopyrronium; Novartis)
  • Seebri (glycopyrronium; Novartis)
  • Daliresp (roflumilast; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Xolair (omalizumab; Novartis/Roche)
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK)

調查課題

  • 各種障礙對市場進入的影響
    • 醫生最大量開立處方的品牌為何?
    • 受市場障礙影響的處方數是多少?
    • 有最大影響的障礙為何?
  • 各品牌的障礙的影響
    • 開立各品牌處方的醫生數是多少?未開立處方但考慮的數量是多少?
    • 不開立處方的理由為何?其替代處方為何?
    • 爭奪市場佔有率的競爭品牌為何?
目錄

Two brands enjoy big market share boosts as market barriers hinder competitors

Market barriers affect more than a third of asthma/COPD prescriptions in the US. According to our survey, roughly 55% of doctors can't prescribe certain brands because they're either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of almost 5% because doctors can't prescribe competitors.

Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 100 US-based pulmonologists and primary care physicians, the report covers 12 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, Novartis , and Roche .

Top Takeaways

  • Barriers affect more than a third of prescriptions: The two biggest barriers have a bigger impact than all other barriers combined.
  • Two brands see impressive market share gains: Each sees a net increase of nearly 5% because barriers prevent doctors from prescribing competing treatments.
  • Most brands lose: 8 of the 12 surveyed brands see a net market share loss, although many of those losses are modest.
  • Few brands are widely prescribed: Only 4 brands are prescribed by more than about 65% of doctors. However, many doctors are willing to consider brands they don't prescribe.
  • More doctors experience cost and formulary availability barriers: Roughly 20-40% of doctors can't prescribe most brands because they're too expensive or not available on formularies.
  • Low awareness is a problem for some brands: 20-30% of doctors simply haven't heard of 4 of the surveyed brands.

Insight into 12 Major Asthma/COPD Drugs

  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Advair (fluticasone/salmetrol; GSK)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Tudorza (aclidinium; AstraZeneca)
  • Anoro (umeclidinium/vilanterol; GSK)
  • Arcapta (indacaterol; Novartis)
  • Utibron (indacaterol/glycopyrronium; Novartis)
  • Seebri (glycopyrronium; Novartis)
  • Daliresp (roflumilast; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Xolair (omalizumab; Novartis/Roche)
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK)

Exploring Market Access Barriers

Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with asthma and/or COPD in total in the last month

We conducted the survey between between June 1st and 5th, 2017.

Back to Top